Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, talks to us about current advancements in studies on pacritinib, a JAK2/FLT3 inhibitor that has been proven to be superior to the best alternative therapy for myelofibrosis (MF), particularly in those with marked thrombocytopaenia, but had previously been put on hold in clinical studies due to concerns with its toxicity. He states that pacritinib has now been reinstated in clinical research and current studies are focused on determining the safest effective dose of the drug for treating MF (NCT03165734). This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.